Pricing Log in Create free account

BioLineRx Ltd. (BLRX) vs CytoMed Therapeutics Limited (GDTC)

BioLineRx Ltd. and CytoMed Therapeutics Limited are both Biotechnology companies. BioLineRx Ltd. and CytoMed Therapeutics Limited are of similar size ($10.3M and $10.2M). CytoMed Therapeutics Limited has the higher net margin (0.00% vs −502.1%) and the higher return on invested capital (0.00% vs −74.3%). Across the 13 metrics below, CytoMed Therapeutics Limited leads on 10 and BioLineRx Ltd. on 3.

Valuation

Metric BLRX GDTC Biotechnology median
P/E n/m n/m 8.50
P/S 6.51 n/m 9.71
P/B 0.55 0.57 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.93 n/m 9.21
Earnings yield (82.84%) (31.82%) (33.15%)
Free cash flow yield (119.61%) (0.38%) (25.50%)

Profitability

Metric BLRX GDTC Biotechnology median
Gross margin 80.03% 0.00% 65.16%
Operating margin (874.28%) — 0.00%
Net margin (502.08%) 0.00% 0.00%
Free cash flow margin (776.29%) 0.00% 0.00%
Return on equity (38.10%) 0.00% (56.36%)
Return on assets (18.21%) 0.00% (48.04%)
Return on invested capital (74.28%) 0.00% 0.00%

Growth

Metric BLRX GDTC Biotechnology median
Revenue growth (TTM) (91.93%) — 6.02%
EPS growth (last fiscal year) 93.72% (68.75%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BLRX GDTC Biotechnology median
Debt to equity 0.40 0.08 0.00
Current ratio 1.20 2.64 4.72
Net debt to EBITDA 1.22 0.86 0.96

Dividend

Metric BLRX GDTC Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BLRX GDTC Biotechnology median
Market cap 10.21m 10.30m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack